



16 December 2020

MEDIA RELEASE TWO

TALK TO THOSE WHO KNOW

The battle for Trikafta has been underway for some time now and Cystic Fibrosis Australia has been getting amazing feedback from the community, from active and vocal individuals who have made it their mission to contact their local MPs in an effort to get the word out on Trikafta.

It is a tough campaign to mount but the arguments speak for themselves. Trikafta, a third generation cystic fibrosis (CF) multi-drug, is one of a kind. This new medicine combines elexacaftor, tezacaftor and ivacaftor into a treatment of unprecedented efficiency and impact.

This is the future of CF in Australia that would otherwise be bleak without it. That's why CFA and the CF community needs to keep the pressure up on decision makers to make sure that Trikafta is on everybody's minds going into March 2021.

90% of Australians with CF will benefit from Trikafta and trial patients showed a decline or halt in lung damage, reduced exacerbations, hospitalisations and antibiotic use.

Nutrition, BMI and mental health outcomes were all positively affected. Incidents of CF-related diabetes were suppressed and less frequent overall.

"Trikafta saves, extends and enriches lives allowing people to dream. That's why it's not fair that commercial negotiations can be allowed to drag on and lives are lost," said Nettie Burke, CEO of CFA.

"Cystic Fibrosis Australia is asking for immediate Compassionate Access for all eligible people following a positive PBAC decision."

"This is an unprecedented move, but Trikafta must be part of the future of CF medicine so people with CF can have a future to look forward to a fulfilling life ahead of them," she added.

If you would like to talk to an inspiring member of our community, someone who has real life experience of Trikafta or has a compelling story to tell, please contact nettieb@cfa.org.au.

CFA has created a Trikafta Portal for the media and community: [CLICK HERE](#). About Cystic Fibrosis: [CLICK HERE](#)

#ENDS#

For Further Information:
Nettie Burke
CEO, Cystic Fibrosis Australia
0404 034294